The Business Behind...
Health Care: Drugs
Transition Therapeutics Inc. (TTHI: NASDAQ)
$3.01 0.16 | 5.61%
05/21/13 - 04:00 PM ET
Company Balance Sheet
| Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 12.75M | 17.99M | 15.72M | 12.47M |
| Receivables | 281.00K | 541.14K | 314.78K | 1.61M |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 19.30M | 24.51M | 26.52M | 41.60M |
| Property, Plant & Equipment, Gross | 211.53K | 1.22M | 1.97M | 1.84M |
| Accumulated Depreciation & Depletion | 0.00 | 805.30K | 1.39M | 1.17M |
| Property, Plant & Equipment, Net | 211.53K | 413.60K | 574.55K | 672.33K |
| Intangibles | 16.99M | 19.66M | 20.01M | 20.45M |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Assets | 17.20M | 20.08M | 20.59M | 21.12M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 36.49M | 44.58M | 47.11M | 62.72M |
| Accounts Payable | 2.28M | 976.09K | 1.98M | 3.12M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 3.44M | 976.09K | 1.98M | 7.00M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 1.45M | 47.21K | 19.71M | 17.91M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 1.45M | 47.21K | 19.71M | 17.91M |
| Total Liabilities | 4.89M | 1.02M | 21.69M | 24.91M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 31.61M | 43.56M | 25.42M | 37.82M |
| Common Par | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Paid In Capital | 175.62M | 177.94M | 156.82M | 142.22M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -146.95M | -137.26M | -138.36M | -108.99M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 2.93M | 2.88M | 6.96M | 4.59M |
| Total Capitalization | 31.61M | 43.56M | 25.42M | 37.82M |
| Total Equity | 31.61M | 43.56M | 25.42M | 37.82M |
| Total Liabilities & Stock Equity | 36.49M | 44.58M | 47.11M | 62.72M |
| Total Common Shares Outstanding | 26.92M | 23.22M | 23.22M | 23.22M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 25.38M | 23.14M | 23.14M | 23.13M |
| Diluted Weighted Shares Outstanding | 25.38M | 23.14M | 23.14M | 23.13M |
| Number of Employees | 16 | 20 | 28 | 28 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with TTHI
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- UserThe 1000 Club
- UserBiotech for Obama Presidency
- ContributorStockerblog.com Canadian Li...
- UserPhels
Latest TTHI Headlines from TheStreet
- 5 Stocks Under $5 Making Big Moves 09.20.12 | 02:09 pm
- 7 Stocks Under $10 With Relative Strength 07.06.12 | 02:07 pm
- 5 Stocks With Huge Insider Buying 12.01.11 | 06:12 am
- Transition Therapeutics Inc. Stock Downgraded (TTHI) 05.23.11 | 08:05 am
- Transition Stock Gaps Up On Today's Open (TTHI) 03.21.11 | 09:03 am
- Transition Therapeutics Inc.: News Release 02.22.11 | 11:02 am
- Transition Stock Soars Higher (TTHI) 02.22.11 | 10:02 am
- Transition Therapeutics Inc. Stock Upgraded By TheStreet Ratings (TTHI) 02.09.11 | 05:02 pm
- Transition Therapeutics Announces Second Quarter Fiscal 2011 Financial Results 02.07.11 | 04:02 pm
- Transition Therapeutics To Hold Conference Call On Second Quarter Fiscal 2011 Financial Results On Monday, February 7th, At 4:30 P.M. EST 02.04.11 | 01:02 pm
Press Releases for TTHI
- Transition Therapeutics To Hold Conference Call On Second Quarter Fiscal 2013 Financial Results On Thursday, February 7th, At 4:30 P.M. EST - PR Newswire 02.04.13 | 12:02 pm
- Transition Therapeutics Announces Enrollment Of The First Patient In Phase 2 Study Of ELND005 (Scyllo-inositol) For The Treatment Of Agitation/Aggression In Patients With Alzheimer's Disease - PR Newswire 11.28.12 | 08:11 am
- Transition Therapeutics To Hold Conference Call On First Quarter Fiscal 2013 Financial Results On Thursday, November 8th, At 4:30 P.M. EST - PR Newswire 11.05.12 | 04:11 pm
- Transition Therapeutics To Hold Conference Call On Full Year Fiscal 2012 Financial Results On Thursday, September 13th, At 4:30 P.M. EST - PR Newswire 09.11.12 | 04:09 pm
- Transition Therapeutics Announces Dosing Of First Patient In Phase 2 Clinical Study Of ELND005 In Bipolar Disorder - PR Newswire 08.30.12 | 07:08 am
- Transition Therapeutics To Present At The Canaccord Genuity Annual Growth Conference - PR Newswire 08.13.12 | 04:08 pm
- LifeSci Advisors Announces Investment Opinion On Transition Therapeutics, Inc. - Business Wire 06.16.11 | 09:06 am
- Elan And Transition Therapeutics Announce Topline Summary Results Of Phase 2 Study And Plans For Phase 3 For ELND005 (Scyllo-inositol ) - Business Wire 08.09.10 | 04:08 pm
Partner Headlines for TTHI
- Transition Therapeutics To Trade Higher Into Upcoming Trial Results For Diabetes Drug - Seeking Alpha 01.28.13 | 09:01 am
- Elan Starts Phase II ELND005 Study - Analyst Blog - NASDAQ 09.06.12 | 08:09 pm
- Transition Therapeutics Announces ELND005 Phase 2 Clinical Trial Data to be Presented at the International Conference of Alzheimer's Disease (ICAD) Meeting - Benzinga 07.15.11 | 04:07 pm
- Morning Market Losers - Benzinga 05.31.11 | 10:05 am
- Morning Market Movers (FONR, TTHI, GFN, CEBK) - Benzinga 02.22.11 | 09:02 am
- Life Sciences Companies Raise Record Amounts of Capital - Seeking Alpha 12.31.10 | 04:12 pm
- Elan to Move ELND005 to Phase III - Analyst Blog - Zacks 08.16.10 | 04:08 pm
